GPP
AVNR

Great Point Partners’s AVANIR PHARMACEUTICALS, INC CL A AVNR Stock Holding History

Great Point Partners’s Portfolio AVNR Stock Details AVNR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-567,000
Closed -$1.91M – 44
2013
Q4 		$1.91M Buy
567,000
+367,000
+184% +$1.52M 1.35% 22
2013
Q3 		$846K Buy
+200,000
New +$948K 0.59% 26

Other funds holding AVNR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
MGM
Miura Global Management New York $25.2M AUM 60.6% 1-Year Est. Return

Great Point Partners's AVNR Position: Q3 2014 in Review

Great Point Partners sold out of AVANIR PHARMACEUTICALS, INC CL A (AVNR) in Q3 2014, closing a stake of 450,000 shares — an estimated $2.54M sold.

Great Point Partners first reported a position in AVNR in Q2 2014 and held it in 1 quarter. The position peaked at $2.54M in Q2 2014. 142 funds tracked by Wall St. Rank hold AVNR as of Q3 2014.

  • Great Point Partners reported no remaining AVANIR PHARMACEUTICALS, INC CL A position as of Q3 2014 after selling out during the quarter.
  • Great Point Partners sold 450,000 AVANIR PHARMACEUTICALS, INC CL A shares in Q3 2014, an estimated $2.54M.
  • Great Point Partners first reported a position in AVANIR PHARMACEUTICALS, INC CL A in Q2 2014 and held it in 1 quarter.
  • Great Point Partners's AVANIR PHARMACEUTICALS, INC CL A position peaked at $2.54M in Q2 2014.
  • 142 funds tracked by Wall St. Rank held AVANIR PHARMACEUTICALS, INC CL A as of Q3 2014.

Based on Great Point Partners's 13F filing for Q3 2014, filed 14 Nov 2014.